title: Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.
abstract: We attempted to clarify the storage iron metabolism from the change in the serum ferritin level. We assumed that the nonlinear decrease in serum ferritin was caused by serum ferritin increase in iron mobilization. Under this assumption, we determined both ferritin and hemosiderin iron levels by computer-assisted simulation of the row of decreasing assay-dots of serum ferritin in 11 patients with normal iron stores free of both iron deficiency and iron overload; chronic hepatitis C (CHC) and iron deficiency anemia after treatment, and 11 patients with iron overload; hereditary hemochromatosis (HH) and transfusion-dependent anemias (TD). We determined the iron removal rates of 20 and 17 mg/day by administering mean doses of deferasirox at 631 and 616 mg/day in 2 TD during the period of balance of iron addition and removal as indicated by the serum ferritin returned to the previous level. The ferritin-per-hemosiderin ratio was almost the same in both HH and CHC. This matched the localized hepatic hemosiderin deposition in CHC with normal iron stores. We detected the ferritin increased by utilizing the hemosiderin iron in iron removal and the ferritin reduced by transforming ferritin into hemosiderin in iron additions. The iron storing capacity of hemosiderin was limitless, while that of ferritin was suppressed when ferritin iron exceeded around 5 grams. We confirmed the pathway of iron from hemosiderin to ferritin in iron mobilization, and that from ferritin to hemosiderin in iron deposition. Thus, serum ferritin kinetics enabled us to be the first to clinically clarify storage iron metabolism.
authors.affiliation: Department of Internal Medicine, Kawamura Hospital, Gifu, Japan. eise@beetle.ocn.ne.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saito
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tomita
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Ohashi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Maeda
authors.forename: Hisao
authors.initials: H
authors.lastname: Hayashi
authors.forename: Tomoki
authors.initials: T
authors.lastname: Naoe
mesh_terms: D000740:Anemia / Q000097:blood; D001565:Benzoates / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003198:Computer Simulation; D000077588:Deferasirox; D005260:Female; D005293:Ferritins / Q000097:blood*; D006432:Hemochromatosis / Q000097:blood; D006485:Hemosiderin / Q000378:metabolism*; D019698:Hepatitis C, Chronic / Q000097:blood; D006801:Humans; D007501:Iron / Q000097:blood*; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000097:blood* / Q000188:drug therapy; D007564:Japan; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D001565:Benzoates; D015415:Biomarkers; D007502:Iron Chelating Agents; D014230:Triazoles; D005293:Ferritins; D006485:Hemosiderin; D007501:Iron; D000077588:Deferasirox